S. Decordova

发表

Identification of 13 novel NLRP7 mutations in 20 families with recurrent hydatidiform mole; missense mutations cluster in the leucine-rich region

Hodges, N. Sebire, R. Fisher, 2009, Journal of Medical Genetics.

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.

H. Gevensleben, Y. Drew, R. Plummer, 2020, Cancer discovery.

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

Rajiv Kumar, U. Banerji, M. Garrett, 2020, Clinical Cancer Research.

A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.

R. Agarwal, U. Banerji, J. Spicer, 2012 .

Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.

A. Tolcher, N. Tunariu, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation

U. Banerji, M. Garrett, R. Ruddle, 2020, Metabolomics.

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.

Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

R. Plummer, N. Tunariu, Juanita Lopez, 2015 .

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Martin O. Leach, Nina Tunariu, Robert A. Beckman, 2014, Clinical Cancer Research.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Gopinath Ganji, J. Tolson, Shanker Kalyana-Sundaram, 2017, Clinical Cancer Research.

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

A. Tolcher, A. Patnaik, M. Garrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.

C. Shapiro, M. Garrett, T. Yap, 2013 .

A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.

Zoe Backholer, Rajiv Kumar, U. Banerji, 2015 .

A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.

R. Herbst, Y. Bang, J. Bono, 2014 .

First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors.

Zoe Backholer, Rajiv Kumar, U. Banerji, 2014 .

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

N. Tunariu, A. Stathis, R. Ruddle, 2023, Nature.

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.